

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

BT-483

RRID:CVCL_2319

Type: Cell Line

Proper Citation

RRID:CVCL_2319

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2319

Proper Citation: RRID:CVCL_2319

Description: Cell line BT-483 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:212572](#), [PMID:10969801](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23151021](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28889351](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BT-483

Synonyms: BT483

Cross References: BTO:BTO_0003470, CLO:CLO_0002043, EFO:EFO_0001095, AddexBio:C0006013/4903, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-121, BioSample:SAMN03471598, BioSample:SAMN10988523, cancercellines:CVCL_2319, Cell_Model_Passport:SIDM00892, ChEMBL-Cells:ChEMBL4295434, ChEMBL-Targets:ChEMBL4296404, Cosmic:687465, Cosmic:809238, Cosmic:871139, Cosmic:877445, Cosmic:894085, Cosmic:897415, Cosmic:904352, Cosmic:934521, Cosmic:949187, Cosmic:1018466, Cosmic:1044221, Cosmic:1046935, Cosmic:1047698, Cosmic:1136343, Cosmic:1152524, Cosmic:1287891, Cosmic:1289384, Cosmic:1603192, Cosmic:1995349, Cosmic:2165017, Cosmic:2750526, Cosmic-CLP:949093, DepMap:ACH-000818, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:949093, GEO:GSM344342, GEO:GSM344392, GEO:GSM350551, GEO:GSM421862, GEO:GSM783946, GEO:GSM827462, GEO:GSM886893, GEO:GSM887958, GEO:GSM1008892, GEO:GSM1053737, GEO:GSM1172854, GEO:GSM1172942, GEO:GSM1215263, GEO:GSM1238129, GEO:GSM1669631, IARC_TP53:18374, IARC_TP53:24359, LiGeA:CCLE_071, LINCS_HMS:50107, LINCS_LDP:LCL-1309, PharmacDB:BT483_110_2019, PRIDE:PXD030304, Progenetix:CVCL_2319, PubChem_Cell_line:CVCL_2319, Wikidata:Q54798468

ID: CVCL_2319

Record Creation Time: 20220427T215414+0000

Record Last Update: 20260829T231647+0000

Ratings and Alerts

No rating or validation information has been found for BT-483.

No alerts have been found for BT-483.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. *Cell chemical biology*, 33(6), 785.

Lin WD, et al. (2024) A novel long non-coding RNA MIR4500HG003 promotes tumor metastasis through miR-483-3p-MMP9 axis in triple-negative breast cancer. *Cell death & disease*, 15(5), 310.

Kunder R, et al. (2022) Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. *Cell chemical biology*, 29(3), 358.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. *Molecular cell*, 81(4), 708.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Mabe NW, et al. (2020) G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program. *Cell reports*, 33(5), 108341.

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Koundouros N, et al. (2020) Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids. *Cell*, 181(7), 1596.

McMillan EA, et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. *Cell*, 173(4), 864.